Torasemide
- Generic Name
- Torasemide
- Brand Names
- Demadex, Soaanz
- Drug Type
- Small Molecule
- Chemical Formula
- C16H20N4O3S
- CAS Number
- 56211-40-6
- Unique Ingredient Identifier
- W31X2H97FB
- Background
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
- Indication
Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.
As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.
- Associated Conditions
- Edema, Hypertension
A Crossover Study of Patients with HF to Compare Natriuretic Effects of IR Torsemide Vs. ER Torsemide Over 12 Hrs
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06708611
- Locations
- 🇺🇸
Future Life Clinical Trials, Miami, Florida, United States
A Dose-finding Study of JMKX003142 in Treatment of Renal Edema
- Conditions
- Edema SecondaryEdema Leg
- Interventions
- Drug: JMKX003142 tablets
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 216
- Registration Number
- NCT06670534
- Locations
- 🇨🇳
Zhejiang Hangyu Pharmaceutical Co., Ltd（subsidiary of Jemincare）, Shanghai, China
Pharmacogenetics of Torasemide and Spironolactone in Hypertension Treatment
- Conditions
- HypertensionGenetic PredispositionDrug Effect
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Ospedale San Raffaele
- Target Recruit Count
- 38
- Registration Number
- NCT06413082
- Locations
- 🇮🇹
San Raffaele Hospital, Milan, Lombardia, Italy
🇮🇹IRCCS Ospedale San Raffaele, Milan, Italy
A Study to Investigate the Effect of Urine Acid-base Disequilibrium on the Pharmacokinetics of Captopril
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06292091
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Optimal Medical Treatment of Difficult-to-treat Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2024-02-23
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- National Institute of Cardiology, Warsaw, Poland
- Target Recruit Count
- 2500
- Registration Number
- NCT06275763
- Locations
- 🇵🇱
National Institute of Cardiology, Warsaw, Mazowieckie, Poland
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Heart Failure, Congestive
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
Effect of Extended Release Torsemide in Patients with Congestive Heart Failure and Overactive Bladder
- Conditions
- Heart FailureOveractive BladderIncontinence
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Sarfez Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT06206512
- Locations
- 🇺🇸
Cardiometabolic Research Unit, Dallas, Texas, United States
Study of Innovative Drug Strategies in Improving Left Ventricular Function After Mitral Repair
- Conditions
- Congenital Mitral Insufficiency
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 164
- Registration Number
- NCT06039592
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Study of Drug Therapy for Pediatric Heart Failure
- Conditions
- Heart Failure Congenital
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 200
- Registration Number
- NCT06039540
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Study of Innovative Drug Treatment Therapy for Pediatric Mitral Regurgitation
- Conditions
- Congenital Mitral Insufficiency
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- China National Center for Cardiovascular Diseases
- Target Recruit Count
- 122
- Registration Number
- NCT06037434
- Locations
- 🇨🇳
Fuwai hospital, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.